Annogen
Annogen B.V. is a Dutch biotechnology company offering gene expression engineering services through its proprietary SuRE™ and AIM™ platforms, serving cell and gene therapy developers, biomanufacturers, and crop engineering companies worldwide.
- Company typePrivate
- Founded2017
- HeadquartersAmsterdam, Netherlands
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Annogen does
Annogen B.V. is a privately held Dutch biotechnology company founded in 2017 and headquartered in Amsterdam, Netherlands. The company provides specialized gene expression engineering services to developers of cell and gene therapies, manufacturers of biopharmaceutical cell lines, and crop engineering programs. Its core technology comprises two proprietary platforms: SuRE™ (Survey for Regulatory Elements), which identifies and optimizes bespoke, patentable promoters and enhancers, and AIM™ (Annogen Integration Site Mapping), which screens expression characteristics across more than 100,000 integration sites in parallel. Outputs from these platforms — designed promoter/enhancer sequences and large-scale expression datasets — constitute the company's core deliverables.
Revenue is generated through project-based professional service engagements in which customers consult Annogen's scientific team directly, supplemented by the sale of Training Data Sets — large-scale genomic datasets packaged for external AI/ML training. The company maintains strategic alliances with academic institutions and advanced therapy companies worldwide, and addresses three distinct customer verticals: cell and gene therapy, manufacturing cell lines, and crop engineering. Annogen is led by founder and CEO Joris van Arensbergen, operates with a team of 11–50 employees, and has not disclosed funding rounds, investors, or revenue figures publicly.
Annogen firmographics
Firmographics- Name
- Annogen
- Legal name
- Annogen B.V.
- Website
- https://annogen.bio
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Annogen B.V. is a Dutch biotechnology company offering gene expression engineering services through its proprietary SuRE™ and AIM™ platforms, serving cell and gene therapy developers, biomanufacturers, and crop engineering companies worldwide.
- Ownership category
- akta.pro rank
Annogen industry classification
Industry- Product category
- Gene Expression Engineering Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
- akta.pro secondary industries
- Lentiviral Vector Gene Therapy Developers (HLAAACAB), Cell Therapy Developers (Autologous) (HLAAABAA), Biotechnology & Gene-Edited Trait Development (AFAGAIAG)
Keywords
Where Annogen is headquartered
LocationHeadquarters
- HQ city
- Amsterdam
- HQ country
- Netherlands
- HQ region
- Europe
Markets served
Annogen business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Gene Expression Engineering Services: Annogen provides specialized services for improvement of gene expression systems for any tissue in any organism, including cell & gene therapy, manufacturing cell lines, and crop engineering applications. Revenue is generated through custom service engagements and project-based work.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Annogen product offering
Product offeringCore offering
Annogen provides custom gene expression engineering services for any tissue in any organism, using its proprietary SuRE™ platform to design bespoke promoters and enhancers and its AIM™ platform to identify favorable transgene integration sites by screening more than 100,000 sites in parallel. The company serves cell and gene therapy developers, biomanufacturers needing optimized production cell lines, and agricultural companies working on crop engineering.
Product overview
Annogen is a gene expression engineering company offering services through two proprietary technology platforms: SuRE™ (Survey for Regulatory Elements) for identifying and optimizing bespoke promoters and enhancers, and AIM™ (Annogen Integration Site Mapping) for analyzing integration sites in parallel. These platforms support three main service areas: Cell & Gene Therapy (including promoter engineering, off-the-shelf promoters, promoter optimization, and expression site identification), Manufacturing Cell Lines, and Crop Engineering (functional genome analysis).
Differentiator
Problem solved
Functional benefit
Brands
- SuRE™: Survey for Regulatory Elements - proprietary platform for identification and optimization of bespoke, patentable promoters and enhancers
- AIM™
Products and services
- SuRE™ (Survey for Regulatory Elements)
Companies that use Annogen
Customer profileSegments3 records
Ideal customer profiles3 records
Annogen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Annogen partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Academic InstitutionscoreAnnogen has forged strategic alliances with renowned academic institutions worldwide, collaborating on gene expression engineering research and development. These partnerships support their commitment to innovation and patient-centric outcomes.
- Advanced Therapy CompaniescoreAnnogen maintains strategic alliances with advanced therapy companies worldwide, supporting the development of transformative therapies through their gene expression engineering platforms and expertise.
Recent moves5 records
Expansion highlights4 records
Annogen competitors and assessment
Company assessmentDirect peers
- Twist Bioscience: Twist offers DNA synthesis and a long-oligo/proprietary promoter library used by gene therapy and synthetic biology customers. It competes with Annogen on gene expression optimization tooling but at much larger scale, bundling promoter services with synthesis orders.
- ATUM (formerly DNA2.0): ATUM provides gene expression engineering services, including proprietary promoter design and protein optimization for therapeutic and industrial customers. Direct overlap with Annogen's SuRE™-driven bespoke promoter offering.
- Synthego: Synthego provides synthetic biology and genome engineering tools, including cell/gene therapy-grade synthetic sgRNAs and gene synthesis services. Targets the same advanced therapy customer segment as Annogen with synthetic biology infrastructure.
- Codex DNA (Telesis Bio): Codex DNA (now Telesis Bio) offers DNA synthesis and synthetic biology workflow automation for therapeutic and research customers, including tools that compete in the gene expression optimization space.
Broad incumbents
- GenScript: GenScript is a large gene synthesis, cell line engineering, and bio-CDMO services provider serving the same cell & gene therapy and biomanufacturing customers as Annogen, with broader portfolio scale.
- Integrated DNA Technologies (IDT): IDT supplies oligonucleotides, synthetic genes, and gene editing tools to gene therapy and molecular biology researchers, with overlapping customer base and adjacent promoter/regulatory element capabilities.
- Eurofins Genomics: Eurofins Genomics provides gene synthesis, promoter design, and broader genomics services for life sciences customers. Overlaps with Annogen in bespoke gene expression services but operates as a much larger diversified services provider.
- Lonza Cell & Gene Therapy: Lonza is a leading CDMO providing cell line development, viral vector manufacturing, and cell therapy services. It competes with Annogen on manufacturing cell line engineering but at industrial scale with full process development.
Emerging players
- Inscripta (now part of Bruker): Inscripta developed a benchtop synthetic biology platform for genome engineering. While its acquisition by Bruker shifts focus, it represents adjacent infrastructure for high-throughput promoter and gene expression engineering.
- TeselaGen: TeselaGen provides a bioinformatics and laboratory informatics platform for synthetic biology and bioprocess R&D, addressing the same customer need for data-driven gene expression workflows but as a software vendor rather than a wet-lab service provider.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Annogen social profiles
Digital presenceAnnogen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Annogen leadership team
Management profileNumber of profiles
Profiles1 record
Annogen funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Annogen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Annogen
What does Annogen do?
Annogen provides custom gene expression engineering services for any tissue in any organism, using its proprietary SuRE™ platform to design bespoke promoters and enhancers and its AIM™ platform to identify favorable transgene integration sites by screening more than 100,000 sites in parallel. The company serves cell and gene therapy developers, biomanufacturers needing optimized production cell lines, and agricultural companies working on crop engineering.
Is Annogen a public or private company?
Annogen is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Annogen founded?
Annogen was founded in 2017. It employs 11 to 50 people.
Where is Annogen based?
Annogen is headquartered in Amsterdam, Netherlands, in the Europe region.
How does Annogen make money?
One revenue line is on record: gene Expression Engineering Services.
Who are Annogen's main competitors?
Direct peers on record are Twist Bioscience, ATUM (formerly DNA2.0), Synthego and Codex DNA (Telesis Bio). Broad incumbents are GenScript, Integrated DNA Technologies (IDT), Eurofins Genomics and Lonza Cell & Gene Therapy. Emerging players are Inscripta (now part of Bruker) and TeselaGen.
Does Annogen have an API?
No public API is recorded for Annogen.
What industry is Annogen in?
Annogen's product category is Gene Expression Engineering Services. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAAACAB, Lentiviral Vector Gene Therapy Developers. Its NAICS code is 541714 and its SIC code is 2835.